Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

33.52
-0.2600-0.77%
Volume:987.64K
Turnover:33.36M
Market Cap:2.40B
PE:-5.68
High:34.28
Open:33.42
Low:33.20
Close:33.78
52wk High:56.05
52wk Low:22.72
Shares:71.71M
Float Shares:52.39M
Volume Ratio:1.01
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:5.90
PE(LYR):-7.19

Loading ...

Otsuka says kidney disease drug preserves function in late-stage study

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)

TIPRANKS
·
Jun 03

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

MT Newswires Live
·
Jun 03

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

TIPRANKS
·
Jun 03

Raymond James sees unique buying opportunity in Vera after FDA alignment

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems

Reuters
·
Jun 02

Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained

TIPRANKS
·
Jun 02

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy

TIPRANKS
·
Jun 02

BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval

Reuters
·
Jun 02

Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026

Reuters
·
Jun 02

Vera Therapeutics, - Revised Origin 3 Egfr Analysis Planned for Q3 2026

THOMSON REUTERS
·
Jun 02

Vera Therapeutics Announces Alignment With U.S. FDA on Earlier Origin Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults With Iga Nephropathy

THOMSON REUTERS
·
Jun 02

Vera Therapeutics, - Pdufa Date Set for July 7, 2026 for Atacicept in Igan

THOMSON REUTERS
·
Jun 02

Vera Therapeutics, - Plans to Submit Sbla in Q4 2026 for Potential Full Approval in 2027

THOMSON REUTERS
·
Jun 02

Vera Therapeutics shareholders elect Class II directors at annual meeting

Reuters
·
May 27

Analysts’ Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)

TIPRANKS
·
May 23

Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)

TIPRANKS
·
May 22

Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden

Simply Wall St.
·
May 22

Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16